All Updates

All Updates

icon
Filter
Funding
Talus Bioscience raises USD 4.3 million in grant funding
AI Drug Discovery
Aug 18, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Aug 18, 2023

Talus Bioscience raises USD 4.3 million in grant funding

Funding

  • Seattle-based AI drug discovery startup Talus Biosciences has secured USD 2.3 million in non-dilutive grant funding from the Andy Hill Cancer Research Endowment (CARE) Fund and an additional USD 2 million small business innovation research (SBIR) grant from the National Institutes of Health, which brings a total fund of USD 4.3 million.

  • The funding will be used to speed up the development of novel transcription factor inhibitors for two pediatric cancers, rhabdomyosarcoma and neuroblastoma, and accelerate the development of transcription factor drugs.

  • Founded in 2020, Talus Biosciences develops novel therapeutics focusing on previously undruggable transcription factors—proteins that regulate all genes in a person's genetic material by attaching to DNA and activating or deactivating the switches that determine gene activity. The company leverages its proprietary drug discovery platform, Multiplexed Assays for Rational Modulation of Transcription Factors (MARMOT), which combines AI, synthetic chemistry, and proteomics to accelerate the discovery and development of novel drugs.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.